Larimar Therapeutics, Inc.
LRMRNext catalyst
CTI-1601
Friedreich Ataxia
Get an email about LRMR's next catalysts
Track Larimar Therapeutics (LRMR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (PDUFA date).See the timeline
2 upcoming, 1 past
CTI-1601 Phase 2 Est. Readout
Primary completion for CTI-1601 trial (NCT06447025) in Friedreich Ataxia
SourceFDA PDUFA Date nomlabofusp (accelerated review)
For Friedreich's Ataxia. BLA submitted. AI-extracted from: Larimar Therapeutics Reports Positive Open Label Data and Submission of First Mo
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nomlabofusp | Phase 3 | Friedreich Ataxia | - | - |
CTI-1601 | Phase 2 | Friedreich Ataxia | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Larimar Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Larimar Therapeutics, Inc.'s (LRMR) pipeline across Phase 3, Phase 2. Its lead program is CTI-1601 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Larimar Therapeutics, Inc.'s next FDA catalyst?→
Larimar Therapeutics, Inc.'s (LRMR) next tracked catalyst is a Phase 2 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LRMR biotech catalysts?→
Add LRMR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Larimar Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.